SCHEMBL3863282

SCHEMBL3863282

O=C(Nc1cccc(O)c1)c1cc(O)cc(O)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.77
MEN1 O00255 2/20 0.77
NPC1 O15118 3/20 0.68
RAB9A P51151 3/20 0.68
MAPK1 P28482 2/20 0.68
TP53 P04637 1/20 0.68
NQO2 P16083 2/20 0.65
LMNA P02545 2/20 0.64
MAPT P10636 2/20 0.64
TOP1 P11387 2/20 0.61
TOP2A P11388 1/20 0.61
TOP2B Q02880 1/20 0.61
ALDH1A1 P00352 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
HTT P42858 1/20 0.60
CYP1A2 P05177 1/20 0.59
PKM P14618 1/20 0.57
KCNK3 O14649 1/20 0.56
KCNK9 Q9NPC2 1/20 0.56
SNCA P37840 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793906 0.91 MEN1 (0.93) KMT2AMEN1NPC1RAB9AMAPK1
SCHEMBL29800565 0.91 MEN1 (0.93) KMT2AMEN1NPC1RAB9AMAPK1
SCHEMBL21707396 0.89 MEN1 (0.89) KMT2AMEN1NPC1RAB9AMAPK1
SCHEMBL11675529 0.87 MEN1 (1.00) KMT2AMEN1NPC1RAB9AMAPK1
SCHEMBL2385408 0.85 KMT2A (0.83) KMT2AMEN1NPC1RAB9AMAPK1
SCHEMBL3656361 0.85 NPC1 (0.78) KMT2AMEN1NPC1RAB9AMAPK1
SCHEMBL4740949 0.85 NQO2 (0.75) KMT2AMEN1NQO2TOP1TOP2A
SCHEMBL23309680 0.82 MEN1 (0.66) KMT2AMEN1NPC1RAB9AMAPK1
SCHEMBL29068810 0.82 DEGS1 (0.72) KMT2AMEN1NPC1RAB9AMAPK1
SCHEMBL28860008 0.82 MEN1 (0.76) KMT2AMEN1NPC1RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1915337-A4 HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME AMOREPACIFIC CORP (KR) 2009-04-22 EP disclosed
US-20080280989-A1 Hydroxybenzamide Derivatives, the Method For Preparing Thereof and the Cosmetic Composition Containing the Same AMOREPACIFIC CORPORATION (KR) 2008-11-13 US disclosed
CN-101243042-A Hydroxybenzamide derivatives, the method for preparing thereof and the cosmetic composition containing the same AMOREPACIFIC CORP (KR) 2008-08-13 CN disclosed
EP-1915337-A1 HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME Amorepacific Corporation (KR) 2008-04-30 EP disclosed
WO-2007021067-A1 HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280989-A1 Hydroxybenzamide Derivatives, the Method For Preparing Thereof and the Cosmetic Composition Containing the Same H1-0, HAAO, H1-10 KMT2A 981/4885MEN1 2695/4885NPC1 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.